Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. a č. 46/2008 Xx. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx dne 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznam xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament Xxxxx republiky x xxxxxxxxx republiky xxxxxxxx xxxxxxx x přijetí xxxx Přílohy X Xxxxxx republikou.

Nové znění Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Pro Xxxxxx xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx X x platnost xxx 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx přestalo xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx pod č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx X x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx text Seznamu xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

SEZNAM XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 a X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené pouze xxx veterinární xxxxxxx), xx xxxxxxxx stále.

S1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:

Androstanolon (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx metabolity x xxxxxxx, xxxxxx, xxx xx x omezením xxxxx na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (SARM, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, např

darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx založené na XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (např. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x luteinizační hormon (XX) x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx, u xxxx.

2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (GH), xxxx xxxxxxxxx a xxxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x hGH 176-191; hormon xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. ghrelin a xxxxxxxx ghrelinu, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Růstové xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx ne s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx);

xxxxxxxxxxxx růstový faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) a xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (MGF);

růstový xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x jeho deriváty, xxxx. TB-500;

vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX).

Xxxxx růstové xxxxxxx x modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx i xxxxxxxxxxxx xxxx-2 agonisté, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx zakázáni.

Zahrnují (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx v xxxxxxxxxx xxxxxxx, nepřekračujících 800 xxxxxxxxxx xxxxx každých 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx dávka 54 mikrogramů xx 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x koncentraci vyšší xxx 1000 xx/xx x xxxxxxxxxx formoterolu x moči x xxxxxxxxxxx vyšší xxx 40 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx výsledek xxx xxxxxxxx terapeutickou xxxxxx (x xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx dávka.

S4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

3. Ostatní antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; a Xxxxxxxx Xxxxxxxxx delta aktivovaného xxxxxxxxxxxxxx proliferátory (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) kyselina xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX A MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx jsou xxxxxxxx, stejně jako xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na ně.

• Acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; indapamid; xxxxxxxx; xxxxxxxx xxxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, chlorothiazid); xxxxxxxxxx a xxxxxxx (xxxx. tolvaptan), ale xx x xxxxxxxx xxxxx xx ně.

S xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx (např. xxxxxxxxxxx x brinzolamidu)

• Lokálního podání xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv množství xxxxx se stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) ve Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Při Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx látku xxxxx x té, xxxxx již xxxx xxxxxxx na xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Podání nebo xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx zvyšování spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Pokus x Xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx na xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx celkem 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních zákroků, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx produkovaných xxxxxxxxx, xxxxxxxxxxx k xxxxxxxxxxx sekvencí genomu x/xxxx k transkripční xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx S5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, např. x- x I-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx výslovně xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx xxxxx xx ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx xxxxxxx (např. xxxxxxxx, methedron x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

S xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx v případě xxxxxx místního/očního xxxxxxx x stimulancií zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx jsou xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 x nejsou xxxxxxxxxx xx Zakázané xxxxx.

** Xxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů v 1 xx moči.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 ml xxxx.

**** Xxxxxxxxx (epinefrin): není xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx aplikace xxxx xxxx podání xxxxxxxx x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. hašiš, xxxxxx x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (THC) x xxxxxxx kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx glukokortikoidy xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx xx s xxxxxxxx pouze xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, a kde xx xx označeno x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x disciplínách xxxxxxxxxx xxxx x ploutvemi xxxx bez xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx nebo xxx xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x variabilní xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Mimo xxxxxx

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 36/2019 Xx. x. x. xxxxx účinnosti xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx xxxxxx, přijatá xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x anglickém xxxxx a x xxxxxxxxx xx xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.